Detalles de la búsqueda
1.
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Clin Infect Dis
; 75(1): e525-e528, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35271729
2.
Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates.
Clin Infect Dis
; 75(1): e1028-e1036, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022711
3.
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Antimicrob Agents Chemother
; 65(5)2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33649113
4.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother
; 76(12): 3286-3295, 2021 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34450619
5.
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001.
J Infect Dis
; 206(9): 1372-85, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22904336
6.
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection.
Antiviral Res
; 209: 105453, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36379378
7.
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
CPT Pharmacometrics Syst Pharmacol
; 12(12): 1859-1871, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37798914
8.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Infect Dis
; 23(2): 183-195, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36272432
9.
Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients.
Biol Blood Marrow Transplant
; 18(5): 731-8, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21963623
10.
First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses.
Antimicrob Agents Chemother
; 56(5): 2726-34, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22391537
11.
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Sci Transl Med
; 14(628): eabl7430, 2022 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34941423
12.
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
Curr Opin Virol
; 50: 17-22, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34271264
13.
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
Trials
; 22(1): 561, 2021 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34425873
14.
Molnupiravir, an Oral Antiviral Treatment for COVID-19.
medRxiv
; 2021 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34159342
15.
Infectious SARS-CoV-2 Virus in Symptomatic COVID-19 Outpatients: Host, Disease, and Viral Correlates.
medRxiv
; 2021 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34100024
16.
Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001.
J Clin Virol
; 50(2): 167-70, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21094081
17.
Development of CMX001 for the Treatment of Poxvirus Infections.
Viruses
; 2(12): 2740-2762, 2010 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-21499452
Resultados
1 -
17
de 17
1
Próxima >
>>